CSL Ltd

CSJ

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    29,904

Stocks News & Analysis

stocks

Ask the analyst: Can this genius product create the next ASX software king?

Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks

Impact of ANZ’s huge fine

Working to prevent repeated failures could also improve competitiveness.
stocks

Acquisition a sign of weakness for overvalued ASX share

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,117.505.00-0.05%
CAC 407,818.2278.71-1.00%
DAX 4023,329.24419.62-1.77%
Dow JONES (US)45,757.90125.55-0.27%
FTSE 1009,195.6681.37-0.88%
HKSE26,438.518.05-0.03%
NASDAQ22,333.9614.79-0.07%
Nikkei 22544,821.0381.24-0.18%
NZX 50 Index13,166.6968.20-0.52%
S&P 5006,606.768.52-0.13%
S&P/ASX 2008,841.706.80-0.08%
SSE Composite Index3,859.562.30-0.06%

Market Movers